SEC Tracker
Get the app

Pfizer PFE

Pfizer's Bourla acquired phantom stock

Albert Bourla (Chairman & CEO) reported option or other derivative trades in PFE

Form
4
Filed
Importance
Routine
  1. Phantom Stock Units acquired on Oct 30, 2026
  2. 20 units settled in cash after separation
  3. Part of Nonfunded Deferred Compensation Plan

Written from the Form 4 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Pfizer files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Amgen AMGN public float $150.1B, Jun 30, 2025
  2. Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025
  3. Gilead Sciences GILD public float $103.2B, Jun 30, 2025
  4. Merck MRK public float $198.1B, Jun 30, 2025
  5. Bristol Myers Squibb BMY public float $94.2B, Jun 30, 2025